Weekly bortezomib with or without glucocorticosteroids is effective in patients with relapsed or refractory multiple myeloma.

被引：0
|
作者：
Suvannasankha, A [1 ]
Smith, GG [1 ]
Abonour, R [1 ]
机构：
[1] Indiana Univ, Ctr Canc, Sch Med, Indianapolis, IN 46204 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2562
引用
收藏
页码：720A / 720A
页数：1
相关论文
共 50 条
  • [1] Bortezomib is cost-effective for the treatment of relapsed and refractory multiple myeloma.
    Mehta, J
    Duff, S
    Gupta, S
    BLOOD, 2003, 102 (11) : 500A - 501A
  • [2] Bortezomib is effective therapy for relapsed multiple myeloma.
    Singhal, S
    Tariman, J
    Smith, K
    Riley, MB
    Mistina, J
    Mehta, J
    BLOOD, 2003, 102 (11) : 390B - 391B
  • [3] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Clinical synergism of Bortezomib and chemotherapy in relapsed and refractory multiple myeloma.
    Mazumder, A
    Chauvin, E
    Curran, K
    Disperati, P
    Jagannath, S
    BLOOD, 2003, 102 (11) : 390B - 390B
  • [5] Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.
    Ghobrial, Irene M.
    Munshi, Nikhil
    Schlossman, Robert
    Chuma, Stacey
    Leduc, Renee
    Nelson, Marybeth
    Sam, Amy
    O'Connor, Kelly
    Harris, Brianna
    Warren, Diane
    Dollard, Akari M.
    Laubach, Jacob
    Vij, Ravi
    Campagnaro, Erica
    Birner, Ann
    Dixon-Lipscomb, Virginia
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2008, 112 (11) : 1266 - 1266
  • [6] Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
    Moore, Sally
    Atwal, Sangeeta
    Sachchithanantham, Sajitha
    Streetly, Matthew
    Khan, Iftekhar
    Percy, Laura
    Narat, Santosh
    D'Sa, Shirley
    Rabin, Neil
    Johnston, Rosalynd
    Schey, Steve
    Yong, Kwee
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (05) : 420 - 425
  • [7] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma
    Gut, Natalia
    Yucebay, Filiz
    Dempsey, Jessica
    Li, Junan
    Benson, Don M., Jr.
    BLOOD, 2018, 132
  • [9] PAD is a highly effective regimen for the treatment of patients with relapsed refractory multiple myeloma.
    Delforge, Michel
    Janssens, Ann
    Dierickx, Dann
    Maertens, Johan
    Theunissen, Koen
    Vandenberghe, Peter
    Verhoef, Gregor
    BLOOD, 2006, 108 (11) : 363B - 363B
  • [10] Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma
    Gozzetti, Alessandro
    Fabbri, Alberto
    Oliva, Stefania
    Marchini, Elena
    Bocchia, Monica
    Defina, Marzia
    Lauria, Francesco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 68 - 72
12345